(Q48101934)

8 February 2018

review article

1 reference

title

Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives (English)

1 reference

8 February 2018

1 reference

4

1 reference

8 February 2018

Sunil W Dutta

object named as

Sunil W Dutta

series ordinal

1

0 references

Bruce Libby

series ordinal

3

object named as

Bruce Libby

1 reference

8 February 2018

Clayton E Alonso

2

1 reference

8 February 2018

publication date

18 December 2017

1 reference

8 February 2018

Expert Review of Medical Devices

published in

1 reference

8 February 2018

volume

15

1 reference

8 February 2018

issue

1

1 reference

8 February 2018

page(s)

71-79

1 reference

8 February 2018

Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

The evolution of brachytherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High dose brachytherapy as monotherapy for intermediate risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Trends in prostate cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

A novel method for accurate needle-tip identification in trans-rectal ultrasound-based high-dose-rate prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate prostate brachytherapy based on registered transrectal ultrasound and in-room cone-beam CT images

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Brachytherapy boost for prostate cancer: Trends in care and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Association Between Androgen Deprivation Therapy and Risk of Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Implanted spacer approaches for pelvic radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17434440.2018.1419058

10.1080/17434440.2018.1419058

21 January 2018

Identifiers

DOI

1 reference

8 February 2018

1 reference

8 February 2018